Newly-Approved Drug Elranatamab for Myeloma

Simone Boothe had spent years fighting two battles at once—multiple sclerosis and an incurable blood cancer called multiple myeloma. The MS symptoms blurred and disguised the early signs of cancer, so by the time she collapsed repeatedly in late 2016, her body was already in crisis. Tests revealed dangerously low hemoglobin and, soon after, the diagnosis that changed everything.

Doctors gave her three to seven years. She endured 41 rounds of chemotherapy, clung to hope, and kept going. Then, in February 2025, she started a newly approved cancer drug, Elranatamab. The effect was nothing short of transformative. For the first time since her diagnosis, Simone is in remission. She calls the treatment “mind‑blowingly successful,” and with her cancer finally quiet, she says her dreams feel possible again.